Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters: Alexandria Bartley, PharmD. Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences Alexis Dunn, PharmD. Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences Adrian Gavre, PharmD Candidate, Philadelphia College of Osteopathic Medicine George McConnell, PharmD. Candidate, LECOM School of Pharmacy Shadrielle Robbins, PharmD Candidate, South College School of Pharmacy Mit Suthar, PharmD. Candidate, LECOM School of Pharmacy | 
There is no doubt that the side effect endpoints a pharma company has to evaluate when they bring a new drug to market have increased over the past 15 years. We often mention that if some of the older diabetes medications had to go through the rigorous studies required today, most of them would have never made it onto the pharmacy shelves.